Review article

Systemic therapy of early breast cancer

Robert Šeparović orcid.org/0000-0002-4002-2699 ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Tajana Silovski orcid.org/0000-0002-4699-5432 ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Robert Zorica ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mirjana Pavlović orcid.org/0000-0002-9633-064X ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ljubica Vazdar ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Vesna Pavlica ; Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Abstract

Breast cancer is the most common cancer in women. Early breast cancer is potentially curable disease. Systemic adjuvant therapy is created to treat micrometastatic disease or destroy breast cancer cells that have spread from the breast and regional lymph nodes, but have not yet formed visible distant metastases. Systemic adjuvant therapy is based on chemotherapy
with or without targeted therapy, and endocrine therapy, sometimes in combination with adjuvant irradiation, usually is conducted after surgery. The aim of adjuvant therapy is to decrease recurrence rate and extension of overall survival

Keywords

breast cancer; micrometastasis; adjuvant chemotherapy; biological therapy; survival rate

Hrčak ID:

199077

URI

https://hrcak.srce.hr/199077

Publication date:

29.12.2014.

Article data in other languages: croatian

Visits: 2.120 *